US5106847A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Excitatory amino acid antagonists, compositions and use
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1991-08-01
•
Granted: 1992-04-21
•
Expires: 2011-08-01
Abstract
Abstract The present invention is directed a new group of indole derivatives that are NMDA antagonists.
Inventors
- 👤 Francesco G. Salituro
- 👤 Bruce M. Baron
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 10:59
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D209/30; C07D209/42; A; A61; A61P; A61P25/00; A61P25/04; A61P25/08; A61P25/20; A61P25/28; A61P43/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
191 words
A compound of the formula: ##STR4## in which T is represented by a C 1-4 alkylene; Z is represented by H, C 1-4 alkyl, phenyl, substituted phenyl, or an alkylphenyl substituent in which the phenyl ring may be optionally substituted; X and Y are each independently represented by a halogen atom; R and R 1 are each independently represented by --OR 2 , --NR 3 R 4 , --OCH 2 OR 2 or --O--(CH 2 ) p --NR 5 R 6 ; R 2 is represented by hydrogen, C 1-4 alkyl, phenyl, substituted phenyl or an alkylphenyl substituent in which the phenyl ring may be optionally substituted; R 3 and R 4 are each independently represented by hydrogen Or a C 1-4 alkyl; p is represented by an integer from 1-4; R 5 and R 6 are each independently represented by a C 1-4 alkyl or together with the adjacent nitrogen atom for a piperidino, morphilino, or pyrrolidinyl group; and the pharmaceutically acceptable addition salts thereof; with the proviso that at least one of R 1 or R must be represented by --O--(CH 2 ) p --NR 5 R 6 .
Claim 2
Dependent Claim
191 words
A compound of the formula: ##STR4## in which T is represented by a C 1-4 alkylene; Z is represented by H, C 1-4 alkyl, phenyl, substituted phenyl, or an alkylphenyl substituent in which the phenyl ring may be optionally substituted; X and Y are each independently represented by a halogen atom; R and R 1 are each independently represented by --OR 2 , --NR 3 R 4 , --OCH 2 OR 2 or --O--(CH 2 ) p --NR 5 R 6 ; R 2 is represented by hydrogen, C 1-4 alkyl, phenyl, substituted phenyl or an alkylphenyl substituent in which the phenyl ring may be optionally substituted; R 3 and R 4 are each independently represented by hydrogen Or a C 1-4 alkyl; p is represented by an integer from 1-4; R 5 and R 6 are each independently represented by a C 1-4 alkyl or together with the adjacent nitrogen atom for a piperidino, morphilino, or pyrrolidinyl group; and the pharmaceutically acceptable addition salts thereof; with the proviso that at least one of R 1 or R must be represented by --O--(CH 2 ) p --NR 5 R 6 .
Claim 3
Dependent Claim
10 words
A compound according to claim 1 wherein T is ethylene.
Claim 4
Dependent Claim
24 words
A compound according to claim 1 wherein R and R 1 are both represented by --O--(CH 2 ) p --NR 5 R 6 .
Claim 5
Dependent Claim
12 words
A compound according to claim 1 in which said compound is 2-dimethylaminoethyl-3-[2-(2-dimethylaminoethoxycarbonyl)-4,6-dichloroindol-3-yl]propionate.
Claim 6
Dependent Claim
12 words
A compound according to claim 1 in which said compound is 2-diethylaminoethyl-3-[2-(2-diethylaminoethoxycarbonyl)-4,6-dichloroindol-3-yl]propionate.
Claim 7
Dependent Claim
13 words
A compound according to claim 1 in which said compound is 2-(4-morpholinyl)ethyl-3-[2-(2-(4-morpholinyl) ethoxycarbonyl)-4,6-dichloroindol-3-yl]propionate.
Claim 8
Dependent Claim
13 words
A compound according to claim 1 in which said compound is 2-(1-pyrrolidinyl)ethyl-3-[2-(2-(1-pyrrolidinyl) ethoxycarbonyl)-4,6-difluoroindol-3-yl]propionate.
Claim 9
Dependent Claim
13 words
A compound according to claim 1 in which said compound is 3-[2-(2-dimethylaminoethoxycarbonyl)-4,6-dichloroindol-3-yl]propionic acid.
Claim 10
Dependent Claim
12 words
A compound according to claim 1 in which said compound is 2-dimethylaminoethyl-3-[2-carboxy-4,6-dichloroindol-3-yl]propionate.
Claim 11
Dependent Claim
33 words
A method for antagonizing the effects of excitatory amino acids upon the NMDA receptor complex comprising administering to a patient in need thereof, an antagonistic amount of a compound according to claim 1.
Claim 12
Dependent Claim
25 words
A method for the treatment of epilepsy comprising administering to a patient in need thereof an anti-epileptic amount of a compound according to claim 1.
Claim 13
Dependent Claim
26 words
A method for the treatment of neurodegenerative diseases comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.
Claim 14
Dependent Claim
27 words
A method for preventing ischemic/hypoxic/hypoglycemic damage to cerebral tissue comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.
Claim 15
Dependent Claim
19 words
A method for the treatment of anxiety comprising administering an anxiolytic amount of a compound according to claim 1.
Claim 16
Dependent Claim
25 words
A method for producing an analgesic effect comprising administering to a patient in need thereof an analgesic amount of a compound according to claim 1.
Claim 17
Dependent Claim
15 words
A composition comprising a compound according to claim 1 in admixture with an inert carrier.
Claim 18
Dependent Claim
15 words
A composition according to claim 16 wherein said inert carrier is a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US4960786A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-04-21 | 1995-10-21 | 1996-04-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-04-21 | 1999-10-21 | 2000-04-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-04-21 | 2003-10-21 | 2004-04-21 | $7700.00 | Window Closed / Lapsed |